Pricing Log in Create free account

Castle Biosciences, Inc. (CSTL) vs NeoGenomics, Inc. (NEO)

Castle Biosciences, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.2B against $1.0B — 2.2× the size. NeoGenomics, Inc. grew revenue faster over the last twelve months: 11.2% against 3.18%. Castle Biosciences, Inc. has the higher net margin (−5.43% vs −6.77%) and the lower return on invested capital (−9.40% vs −4.20%). Across the 18 metrics below, Castle Biosciences, Inc. leads on 13 and NeoGenomics, Inc. on 5.

Valuation

Metric CSTL NEO Diagnostics & Research median
P/E n/m n/m 35.56
P/S 2.72 2.82 4.37
P/B 2.07 2.75 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA n/m n/m 24.35
EV/Sales 2.00 3.38 5.51
Earnings yield (2.07%) (2.40%) (1.89%)
Free cash flow yield (0.05%) (0.25%) (0.15%)

Profitability

Metric CSTL NEO Diagnostics & Research median
Gross margin 77.26% 43.92% 50.89%
Operating margin (8.99%) (8.93%) (8.57%)
Net margin (5.43%) (6.77%) (6.37%)
Free cash flow margin (0.13%) (0.69%) 0.00%
Return on equity (4.20%) (6.33%) (2.92%)
Return on assets (3.51%) (3.78%) (6.71%)
Return on invested capital (9.40%) (4.20%) 0.00%

Growth

Metric CSTL NEO Diagnostics & Research median
Revenue growth (TTM) 3.18% 11.19% 7.69%
EPS growth (last fiscal year) (233.87%) (35.48%) 25.92%
Revenue growth, 5-year CAGR 40.60% 10.35% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSTL NEO Diagnostics & Research median
Debt to equity 0.02 0.48 0.11
Current ratio 6.04 3.60 2.02
Net debt to EBITDA 46.20 (3.96) 0.70

Dividend

Metric CSTL NEO Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric CSTL NEO Diagnostics & Research median
Market cap 1.03b 2.22b 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack